GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show
GSK is set to acquire U.S.-based Nuvalent for $10.6 billion in cash, making it the largest deal GSK has made in years. The offer is $124 per share, which works out to a 40% premium on Nuvalent’s previous closing price. It’s an early move by CEO Luke Miels as he looks to revamp the British group’s oncology pipeline.
